Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in Aggressive Cutaneous Squamous Cell Carcinoma
NCT01059305Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2011
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in cutaneous squamous cell carcinoma (cSCC), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2011; status: terminated.
02
Drugs
erlotinib
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT01059305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01059305.